tti-101
tti-101: sourced relationships with 1 company · 6 clinical trials tracked.
tti-101 evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could tti-101 → TVRD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Tvardi Therapeutics, Inc. (TVRD) Breast Cancer; Hepatocellular Carcinoma; Idiopathic Pulmonar… | Phase 2 |
Clinical Trial Registry Records (6)
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary endpoint: Overall Response Rate (ORR)
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
Primary endpoint: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Primary endpoint: Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of TTI-101 and SBRT
REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Primary endpoint: Number of Participants with an Adverse Event (AE)
REVERT- Liver Cancer: A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Primary endpoint: Incidence of Adverse Events (AE)
REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Primary endpoint: Phase 1b: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
Frequently asked questions
Which companies have sourced relationships with tti-101?
tti-101 has dated SEC/FDA relationship records for Tvardi Therapeutics, Inc..
How many clinical trials involve tti-101?
BioSniper tracks 6 clinical trials involving tti-101.